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Abstract
Matriptase, a type 2 transmembrane serine protease, is
predominately expressed by epithelial and carcinoma cells in
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which hepatocyte growth factor activator inhibitor 1 (HAI-1), a
membrane-bound, Kunitz-type serine protease inhibitor, is also
expressed. HAI-1 plays dual roles in the regulation of
matriptase, as a conventional protease inhibitor and as a factor
required for zymogen activation of matriptase. As a
consequence, activation of matriptase is immediately followed
by HAI-1-mediated inhibition, with the activated matriptase being
sequestered into HAI-1 complexes. Matriptase is also
expressed by peripheral blood leukocytes, such as monocytes
and macrophages; however, in contrast to epithelial cells,
monocytes and macrophages were reported not to express
HAI-1, suggesting that these leukocytes possess alternate, HAI-
1-independent mechanisms regulating the zymogen activation
and protease inhibition of matriptase. In the present study, we
characterized matriptase complexes of 110 kDa in human milk,
which contained no HAI-1 and resisted dissociation in boiling
SDS in the absence of reducing agents. These complexes were
further purified and dissociated into 80-kDa and 45-kDa
fragments by treatment with reducing agents. Proteomic and
immunological methods identified the 45-kDa fragment as the
noncatalytic domains of matriptase and the 80-kDa fragment as
the matriptase serine protease domain covalently linked to one
of three different secreted serpin inhibitors: antithrombin III, α1-
antitrypsin, and α2-antiplasmin. Identification of matriptase-
serpin inhibitor complexes provides evidence for the first time
that the proteolytic activity of matriptase, from those cells that
express no or low levels of HAI-1, may be controlled by
secreted serpins.
MATRIPTASE (also known as MT-SP1, TADG15, ST-14, and epithin) and
hepatocyte growth factor activator inhibitor 1 (HAI-1) are a cognate pair of
epithelium-derived, membrane-bound, serine protease, and Kunitz-type
serine protease inhibitors (12, 17, 18, 30, 32). The functional relationship
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between matriptase and HAI-1 was initially recognized by the purification
of matriptase-HAI-1 complexes from human milk (17). Matriptase-HAI-1
complexes were also detected in the conditioned media of cultured breast
cancer cells and immortal mammary epithelial cells (3, 19). Subsequently,
concordant expression of matriptase and HAI-1 was seen in human breast
and ovarian cancer cell lines (23). Both proteins are broadly coexpressed by
the epithelial component of nearly all epithelium-containing organ systems
(10, 26). More recently, significant expression correlation between
matriptase and HAI-1 at the RNA level was further emphasized by a
transcriptional profiling study with the use of microarray data from 2,000
human normal and cancerous samples, including tumor samples from 18
different tissue types, 59 cancer-derived cell lines, and 86 types of
nonpathogenic tissues (4).
In addition to this expression correlation and the formation of complexes in
vivo and in vitro, an intimate functional linkage between matriptase and
HAI-1 was clearly demonstrated during embryonic development and the
tumorigenesis of epithelial cells (29). Matriptase and HAI-1 are coexpressed
in chorionic trophoblasts during early development of the mouse placenta.
Genetic ablation of HAI-1 causes placenta defects leading to embryonic
death due to the loss of undifferentiated chorionic trophoblasts and impaired
formation of the labyrinth layers (7, 29, 31). Genetic ablation of matriptase
in HAI-1-deficient mouse embryos corrects the impaired processes of
placentation caused by HAI-1 ablation (29). Therefore, coexpression of
HAI-1 and matriptase is not required for placental development. However,
HAI-1 must be expressed if matriptase is expressed, but placentation
proceeds normally in embryos lacking both HAI-1 and matriptase. The close
functional relationship between matriptase and HAI-1 is also observed in
the skin of zebrafish (5). The loss of epithelial integrity in the HAI-1-
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deficient zebrafish epidermis can be rescued by simultaneous inactivation of
matriptase. The functional linkage between matriptase and HAI-1 also has
important implications for the development of cancer. Matriptase activity
that is only partially opposed by endogenous HAI-1 causes increased
carcinogen sensitivity and produces spontaneous tumorigenesis in the skin
of keratin-5-matriptase transgenic mice (21). Matriptase-induced malignant
transformation and its strong prooncogenic potential can, however, be
counteracted by increasing epidermal HAI-1 expression (21). The close
functional relationship of this cognate pair of protease and protease
inhibitor has also been observed at the cellular and subcellular levels.
Enforced expression of matriptase in breast cancer cell lines that do not
naturally express the enzyme only results in the production of significant
amounts of protein when HAI-1 is coexpressed (24, 27). In the absence of
functional HAI-1, matriptase is only produced at very low levels and fails to
traffic out of the endoplasmic reticulum/Golgi apparatus (24). In breast
cancer cells that express both proteins, reducing expression of HAI-1 by
small interfering RNA (siRNA)-mediated HAI-1 knockdown resulted in
spontaneous zymogen activation of matriptase and significantly enhanced
the zymogen activation of matriptase induced by sphingosine 1-phosphate
(24). Unexpectedly, HAI-1 is required for matriptase activation (27), and, as
a consequence, zymogen activation of matriptase is immediately followed
by HAI-1-mediated inhibition of the active matriptase. Consistent with the
dual roles of HAI-1 as a conventional protease inhibitor and as a cofactor
for matriptase zymogen activation, activated matriptase has been
consistently detected in HAI-1 complexes (3, 14).
In light of the pivotal role of HAI-1 in the expression, zymogen activation,
and inhibition of matriptase and in light of the data from the animal models,
it is perhaps not surprising that a growing body of evidence shows that the
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tight expression correlation and close functional linkage of matriptase and
HAI-1 may be altered or lost during the progression of human ovarian
cancer. Both matriptase and HAI-1 are expressed by ovarian surface
epithelial cells (25). However, expression of matriptase in the absence of
HAI-1 or with very low levels of HAI-1 was observed in primary human
ovarian carcinomas, particularly in advanced disease (25). Similar
imbalances between matriptase and HAI-1 expression have been noted in
other cancers of epithelial origin, particularly in the context of more
advanced or aggressive disease, suggesting that this imbalance may play a
significant role in carcinogenesis and tumor progression (28).
It is, therefore, surprising that there are some normal cell types that have
been reported to express matriptase in the absence of HAI-1. Matriptase
messenger RNA (mRNA) has been detected in peripheral blood leukocytes
(30). The THP-1 human monocytic cell line has been reported to express
matriptase but no HAI-1 (11). Matriptase mRNA is present in mouse
peritoneal macrophages but not in bone marrow macrophages; however,
HAI-1 is not detectable in macrophages of either type (4). These data and
the finding that some tumors of epithelial origin apparently express
matriptase in the absence of HAI-1 suggest that there must be a HAI-1-
independent mechanism at work that can facilitate the expression,
trafficking, activation, and inhibition of matriptase in these cells. HAI-1-
independent matriptase expression by cells may lead to the release of active,
non-HAI-1-complexed matriptase.
In the present study, we identified novel matriptase-containing complexes in
human milk that contain no HAI-1. Further purification of these complexes
followed by analysis with mass spectrometry-based protein identification
and confirmation by immunoblotting studies demonstrated that they contain
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secreted serpin-type serine protease inhibitors, including antithrombin III
(ATIII), α1-antitrypsin (α1AT), and α2-antiplasmin (α2AP). The existence
of these matriptase-serpin complexes in human milk suggests that serpins
may play an important role in regulating the activity of matriptase,
particularly in the context of cell types that express matriptase in the
absence of measurable HAI-1.
MATERIALS AND METHODS
Chemicals and reagents.
Human plasma ATIII was purchased from Innovative Research (Southfield,
MI). Human plasma α1AT was purchased from Sigma (St. Louis, MO).
Human plasma α2AP was purchased from Haematologic Technologies
(Essex Junction, VT). CM-Sepharose and activated Sepharose beads were
obtained from GE Healthcare (Piscataway, NJ). All other chemical reagents
were obtained from Sigma unless otherwise specified.
Monoclonal antibodies.
Human matriptase protein was detected with either the M32 monoclonal
antibody (mAb), which recognizes the third LDL receptor class A domain of
matriptase in both the latent (one chain) and activated (two-chain) forms of
the protease, or with the M69 mAb, which recognizes an epitope present
only in the activated (two-chain) form of the enzyme (1, 2). Human HAI-1
was detected with the use of the HAI-1-specific mAb M19 (17). ATIII and
α2AP polyclone antibodies were purchased from R&D Systems
(Minneapolis, MN). α1AT polyclone antibody was purchased from Bethyl
Laboratories (Montgomery, TX).
Immobilization of mAbs.
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mAbs M19, M69, and 21-9 were covalently coupled to Sepharose 4B at 5
mg/ml gel following the manufacturer's instructions (GE Healthcare).
Briefly, the mAbs were purified and dialyzed against the coupling buffer
(0.1 M sodium bicarbonate containing 0.5 M sodium chloride) and
incubated overnight at 4°C with cyanogen bromide-activated Sepharose 4B.
The uncoupled mAbs were removed by washing the beads with the coupling
buffer, and the residual coupling sites on beads were blocked by 1 M Tris
buffer. The mAb-Sepharose beads were stored in PBS.
Purification of the 110-kDa matriptase complexes from human milk.
Frozen human milk from Georgetown University Medical Center Milk Bank
was thawed and centrifuged to remove the milk fat and insoluble debris. The
defatted milk was dialyzed against 10 mM phosphate buffer, pH 6.0, and
loaded onto a CM-Sepharose FF column (2.5 × 20 cm; GE Health Science)
equilibrated with 10 mM phosphate buffer, pH 6.0. The column was washed
with 10 column volumes of equilibrium buffer. Proteins were eluted with a
linear gradient of 0–0.5 M NaCl in 10 mM phosphate buffer, pH, 6.0, with a
total volume of 500 ml. The column fractions containing 110-kDa
complexes were collected and pooled. To remove the 95-kDa matriptase-
HAI-1 complexes from the 110-kDa matriptase complex-enriched fractions,
the samples were loaded onto a HAI-1 immunoaffinity column containing 1
ml mAb M19-Sepharose at a flow rate of 7 ml/h. The flow through, which
contained the 110-kDa complexes, was then loaded onto a matriptase mAb
21-9 immunoaffinity column and the column washed with 1% Triton X-100
in PBS. Bound proteins then were eluted with 0.1 M glycine HCl, pH 2.4.
Fractions were immediately neutralized by addition of 2 M Trizma base.
Western blotting.
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Protein samples for Western blotting were diluted in 5× sample buffer. The
sample buffer did not contain a reducing agent, and samples were not boiled
before SDS-PAGE unless otherwise specified since reducing agents destroy
the epitopes recognized by the mAbs and boiling disrupts matriptase-HAI-1
complexes. Proteins were resolved by 7.5% SDS-PAGE, transferred to
Protran nitrocellulose membranes (Schleicher & Schuell, Keene, NH), and
probed with the mAbs M32, M69, and M19 or the polyclonal antibodies
directed against serpins. The binding of the primary antibody was detected
with the use of horseradish peroxidase-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grove, PA) and visualized
using the Western Lightening Chemiluminescence Reagent Plus (Perkin-
Elmer, Boston, MA).
Diagonal SDS-PAGE.
The 110-kDa complex was first boiled with SDS sample buffer in the
absence of reducing agents and then resolved by electrophoresis. A gel strip
was then sliced out from the gel used in the previous step and boiled with
SDS sample buffer containing reducing agent. The reducing agent-treated
strip was placed on the top of a new gel and subjected to electrophoresis in
the second dimension, at 90 degrees to that in the first gel. Protein and
protein fragments were assayed by colloidal Coomassie blue staining of the
second gel.
Liquid chromatography/mass spectrometry analysis and identification
of proteins.
The selected bands from the gels were initially excised, washed, destained,
and trypsinized overnight at 37°C using standard protocol after DTT
reduction and iodoacetamide alkylation. Liquid chromatography/mass
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spectrometry (LC/MS) analysis of tryptic peptides derived from protein
samples were performed on Thermo Finnigan LCQ DECA XP mass
spectrometer (ThermoFinnigan, San Jose, CA), which was connected to a
nanoelectrospray ionizer. The Surveyor LC system with auto sampler
(ThermoFinnigan) was used for peptide separation. The LC system was
connected to a 10.5-cm fused silica reverse-phase C18 column (PicoFrit
column; New Objective, Woburn, MA). The peptides were separated during
90 min of linear gradient of 5–90% acetonitrile/water mixture, containing
0.1% formic acid at a flow rate of 300 nl/min. MS scan events and HPLC
solvent gradients were controlled by the Xcalibur software
(ThermoFinnigan). The spectrums were accumulated in data-dependant
acquisition mode, and the acquired MS/MS scans were searched against the
human database (IPI) using SORCERER/SEQUEST search algorithm.
Database search parameters were set to allow carboxyamidomethylation
(+57.021464 Da) of cysteine residues and oxidation (15.99492 Da) of
methionine as fixed modification. The best hit was selected on the basis of
probability/percent of coverage and number of peptides or on the basis of
Xcore.
RESULTS
Identification of matriptase complexes, which contain no HAI-1.
During lactation, mammary epithelial cells robustly activate matriptase
immediately followed by HAI-1-mediated inhibition of active matriptase
and the shedding into the milk of matriptase-HAI-1 complexes with a size
of 95 kDa (17). Although the physiological role of matriptase zymogen
activation during lactation remains to be determined, human milk is
apparently one of the best systems in which to characterize the diverse roles
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of this type 2 transmembrane serine protease. When human milk was
fractionated by CM-Sepharose chromatography, minor matriptase
complexes with an apparent mass of 110 kDa were eluted and partially
separated in different column fractions (Fig. 1A, fractions 18 through 24)
from the majority of the matriptase detected in 95-kDa complexes (Fig. 1A,
fractions 10 through 21). The 95-kDa matriptase protein bands were further
confirmed to be HAI-1 complexes by blotting with the HAI-1 mAb M19
(Fig. 1B), consistent with our previous study (17). In contrast, the minor
110-kDa matriptase-containing complexes apparently do not contain HAI-1
since they were not detected by the HAI-1 mAb M19 (Fig. 1B).
To characterize and compare the novel 110-kDa matriptase-containing
complexes with the matriptase-HAI-1 complexes, fractions containing
roughly equal amounts of both 95-kDa HAI-1 complexes and 110-kDa
complexes (such as fraction 21 in Fig. 1 and Fig. 2A, lane 1) were subjected
to immunoprecipitation experiments with the use of immobilized matriptase
and HAI-1 mAbs (Fig. 2A). When both the 95-kDa and 110-kDa complexes
were incubated with immobilized matriptase mAb 21-9 on Sepharose beads
(18), both complexes bound efficiently to the beads and were
immunodepleted from the solution (Fig. 2A, lane 2), confirming that both
complexes contain matriptase. In contrast, immobilized HAI-1 mAb M19
only resulted in immunodepletion of the 95-kDa complexes and not the 110-
kDa complexes [Fig. 2A, M19 immunoprecipitation (IP), unbound (UB),
lane 8], confirming the results from immunoblot blot analyses in Fig. 1 that
the 110-kDa complexes contained no HAI-1. In addition to the matriptase
mAbs M32 and 21-9 and the HAI-1 mAb M19, we have developed unique
mAbs that can distinguish the latent from the activated form of matriptase
(1). These activated matriptase-specific mAbs have been used in our
previous studies for the characterization of matriptase activation in vivo and
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in vitro (1, 2, 8, 13, 14, 16). When both the 110-kDa and 95-kDa matriptase
complexes were incubated with Sepharose beads linked to the activated
matriptase-specific mAb M69, only 95-kDa matriptase-HAI-1 complexes
and not the 110-kDa complexes were immunodepleted from the solution
(Fig. 2A, M69 IP, UB, lane 5), suggesting that the unique, activation-
associated epitope recognized by mAb M69 is not present on the 110-kDa
complexes. To confirm that the immunodepletion seen in these experiments
was indeed due to the complexes binding to the antibody beads, the bound
proteins were eluted and subjected to Western blot analysis. The beads were
washed, and the bound proteins were eluted with 0.1 M glycine buffer, pH
2.4, and immediately neutralized by Trizma base. This elution procedure
was repeated twice, yielding two samples for each set of beads (E1 and E2).
Analysis of these eluates demonstrated that the 95-kDa matriptase-HAI-1
complexes were liberated from the beads as both the original 95-kDa
complex and as a 70-kDa band size expected for uncomplexed matriptase
(Fig. 2A, lanes 3, 4, 6, 7, 9, and 10), consistent with the features of a Kunitz
inhibitor of HAI-1, which shows acid sensitivity and reversible binding and
inhibition to matriptase (1). The 110-kDa complexes were also eluted from
the matriptase mAb 21-9-Sepharose (Fig. 2A, lanes 3 and 4) but not from
the mAb M19-Sepharose (Fig. 2A, lanes 9 and 10) or the mAb M69-
Sepharose (Fig. 2A, lanes 6 and 7), consistent with the immunodepletion
results. The differential binding of both matriptase-containing complexes to
the HAI-1 mAb not only demonstrates the novelty of the 110-kDa
matriptase-containing complexes but also provides the biochemical means
for the separation and purification of the novel matriptase-containing
complexes from the predominant HAI-1-containing complexes.
Purification and biochemical characterization of milk-derived 110-
kDa matriptase complexes.
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We further purified the novel matriptase-containing complexes from the
110-kDa complex-enriched CM-Sepharose column fractions by using a
matriptase mAb 21-9-Sepharose immunoaffinity column after removal of
the matriptase-HAI-1 complexes with an immobilized HAI-1 mAb M19
immunoaffinity column (Fig. 2B). The fractions eluted from the matriptase-
immunoaffinity column were analyzed by a one-dimensional SDS PAGE
under both nonboiled and boiled conditions (Fig. 2B) and then a two-
dimensional, diagonal gel electrophoresis under reducing conditions (Fig.
3). The 110-kDa complexes represented the major protein band in the eluted
fraction (Fig. 2B, lane 1). Boiling of the sample with SDS did not cause
dissociation of the complexes but resulted in a slightly slower rate of
migration on SDS-PAGE (Fig. 2B, lane 2). Western blot analysis confirmed
that the 110-kDa protein bands were matriptase-containing complexes (Fig.
2C). These analyses suggest that there was a covalent linkage between the
matriptase and its binding partner(s) in these complexes, distinct from the
noncovalent interactions between matriptase and HAI-1, which can be
dissociated by boiling (17) or by acidic pH (1). Interestingly, after boiling in
the presence of SDS, we observed that the 110-kDa band apparently
contained more than one species (Fig. 2B, lane 2). To analyze the
constituents of the 110-kDa complexes, a strip of SDS polyacrylamide gel
containing the 110-kDa species was sliced from the gel, chemically reduced
using 50 mM DTT, and then subjected to electrophoresis in a second SDS
polyacrylamide gel (diagonal gel electrophoresis). Diagonal gel
electrophoresis is a useful tool to analyze protein complexes since those
proteins whose rates of migration are the same or similar before and after
exposure to reducing agents will appear on a diagonal line; however, protein
complexes whose subunits dissociate will yield bands on the same path on
the gel under the diagonal line. After this procedure, the 110-kDa complexes
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were dissociated into bands of 80 kDa and 45 kDa (Fig. 3). These data
suggest that 110-kDa matriptase complexes contain two disulfide-linked
fragments of 80 kDa and 45 kDa.
Milk-derived 110-kDa matriptase complexes contain the secreted
serpin inhibitors ATIII, α1AT, and α2AP.
Both the 80-kDa and 45-kDa protein bands were subjected to MS-based
protein identification studies as described in the MATERIALS AND METHODS
(Fig. 3). The 80-kDa protein bands contained multiple proteins. Tryptic
fragments derived from this protein band contain five peptides matched to
matriptase, 30 peptides matched to ATIII, three peptides matched to α1AT,
and two matched to α2AP. Eleven tryptic peptides derived from the 45-kDa
protein bands were matched to matriptase (Fig. 3). Interestingly, the five
tryptic peptides derived from the 80-kDa bands, which matched to
matriptase, were all located within the serine protease domain of matriptase,
whereas, the matriptase-matching tryptic peptides from the 45-kDa bands
were all localized in the noncatalytic domains of matriptase. These data
suggest that the 110-kDa complexes contain disulfide-linked, two-chain,
activated matriptase. Considering the molecular mass of the three serpins
identified (∼55 kDa for ATIII, ∼60 kDa for α1AT, and ∼70 kDa for α2AP)
and of the serine protease domain of matriptase (25 kDa), it seems very
likely that the 80-kDa bands are composed of three different complexes of
the matriptase serine protease domain with one or other of these three
serpins. Therefore, the 110-kDa complexes are likely to be a mixture of
matriptase-ATIII, matriptase-α1AT, and matriptase-α2AP complexes.
We further confirmed that the 110-kDa matriptase complexes are a mixture
of matriptase associated with each of the three secreted serpins by
immunoblot with ATIII, α1AT, and α2AP polyclonal antibodies and the
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matriptase mAb M32 (Fig. 4). The 110-kDa complexes and the various
serpins were subjected to SDS-PAGE and then blotted with each of the four
antibodies, respectively. The 110-kDa complexes were recognized by the
matriptase mAb M32 and all three serpin polyclonal antibodies (Fig. 4,
A–D, lane 1). The matriptase mAb M32 did not interact with these three
serpin proteins (Fig. 4A, lanes 2, 3, and 4); the serpin polyclonal antibodies
only interacted with their corresponding proteins and not the other serpins
(Fig. 4, B–D, lanes 2, 3, and 4).
In contrast to Kunitz-type serine protease inhibitors such as HAI-1, serpin-
type serine protease inhibitors, including ATIII, α1AT, and α2AP, inhibit
proteases by forming covalent-linked complexes in a suicide mode (9, 34).
This unique feature of serpin-type inhibitors is consistent with the resistance
to dissociation by boiling SDS in the absence of reducing agents exhibited
by the 110-kDa matriptase-serpin complexes (Fig. 2). Interestingly,
chemical reduction of the 110-kDa matriptase-serpin complexes cleaved the
disulfide-linkage between the serine protease domain and noncatalytic
domain of matriptase in the complexes and resulted in the release of the
noncatalytic domains of matriptase, seen as the 45-kDa protein band in the
diagonal gel electrophoresis study (Fig. 3). After releasing the 45-kDa
matriptase noncatalytic domain, the 110-kDa complexes were converted
into 80-kDa complexes consisting of the matriptase serine protease domain
covalently linked with either ATIII, α1AT, or α2AP. In Fig. 4E, we
summarize the structure of 110-kDa complexes and the conversion into their
subunits by chemical reduction.
Matriptase and its inhibitors in human milk.
We further analyzed the expression status of matriptase and its endogenous
inhibitors, including HAI-1, ATIII, α1AT, and α2AP in defatted human milk
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(Fig. 5). Matriptase was detected predominantly in its 95-kDa HAI-1
complexes and also as a minor species at 110-kDa, which may represent a
mixture of matriptase complexes with the individual secreted serpins (Fig.
5, lane 1). There was no free (noncomplexed) matriptase, either in its latent
or activated form, detected in human milk. The activated matriptase-
specific mAb M69, only detected the 95-kDa matriptase-HAI-1 complexes
(Fig. 5, lane 2), further confirmed that there was no free, active matriptase
in human milk. HAI-1 was detected only in 95-kDa matriptase complex,
demonstrating that there was also no free (noncomplexed) HAI-1 (Fig. 5,
lane 3). In contrast, free (noncomplexed) ATIII and α1AT were detected in
human milk in addition to the complexed forms (Fig. 5, lanes 4 and 5).
Hematopoietic cells express matriptase with no or very low levels of
HAI-1.
In search of cell types that utilize different mechanisms that do not involve
HAI-1 for the regulation of matriptase, we turned our attention to
hemopoietic cells, some of which previously were reported to express
matriptase in the absence of HAI-1 (4, 11). Western blot analysis of human
leukemia and lymphoma cell lines for the expression of matriptase and
HAI-1 was performed (Fig. 6). T-47D human breast cancer cells, which
express high levels of both matriptase and HAI-1, were used as a control.
Western blotting with the matriptase mAb M32 revealed that THP-1, human
monocytic cells, and two Burkitt's lymphoma cells, Daudi and ST486, were
positive for the protease, whereas the seven others were negative (Fig. 6).
Although low levels of HAI-1 were detected in some cells that express no
matriptase, neither Daudi nor ST486 cell lines coexpressed HAI-1 with
matriptase. THP-1 cells express HAI-1 at very low levels compared with the
T-47D cells and even the other HAI-1-positive leukemia cell lines. These
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expression analyses suggest that some hematopoietic cells are likely using
HAI-1 as an independent mechanism for the regulation of matriptase and
that the secreted serpins identified in the present study may serve as
endogenous inhibitors for matriptase derived from these hematopoietic
cells.
DISCUSSION
The identification of matriptase complexed with secreted serpins,
particularly ATIII and α1AT, in human milk provides evidence that free,
active matriptase indeed exists extracellularly either on the cell surface or in
the interstitial space of lactating mammary glands, where free, active
matriptase encounters these secreted serpins. As a membrane-bound serine
protease with a single-pass transmembrane domain, the bulk of the
matriptase molecule, including its serine protease domain, has been
believed to orient itself toward the extracellular side and to function as a
protease activator on the cell surface to activate substrates extracellularly
(17). However, the dual roles of HAI-1 as a conventional protease inhibitor
for matriptase (1) and as a factor required for zymogen activation of the
protease (27) would seem to dictate that free, active matriptase is only
likely to exist for a very short time. Activated matriptase has been
consistently detected in complexes with HAI-1 regardless of the cell source,
such as breast cancer cells vs. immortal mammary epithelial cells (2),
regardless of the mode of zymogen activation, such as the constitutive
activation exhibited by breast cancer cells (2) compared with the induced
zymogen activation in immortal mammary epithelial cells by sphingosine 1-
phosphate (2), or in prostate cancer cells by androgen (13), or more broadly
in other cell types by suramin (16). Although it has been challenging to
determine the exact cellular locations where the activation of matriptase
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occurs, it seems likely that it takes place either at the plasma membrane or
in the secretory pathway during its trafficking toward the plasma membrane
because activated matriptase was previously detected at cell-cell junctions
(2, 8) and in vesicle-like structures within cells (16). In either case, given
that HAI-1 participates in the activation process and is therefore present and
able to immediately bind to the newly activated enzyme, the accessibility of
free, active matriptase to its potential extracellular substrates, or to protease
inhibitors other than HAI-1, may be very limited. Therefore, in matriptase-
expressing cells that also express a comparable amount of HAI-1, free,
active matriptase may never reach the extracellular environment at
meaningful levels. It is, therefore, paradoxical that, in the present study, we
purified matriptase complexed with secreted serpins from human milk. The
ATIII and α1AT are probably derived from blood or locally produced during
lactation and deposited in the extracellular matrix (33). Furthermore,
serpins are activated after secretion, and, therefore, it is unlikely that
inhibition and formation of matriptase-serpin complexes occur in the
secretory pathway. Therefore, free, active matriptase has to reach the
extracellular environment, at least on the extracellular surface of the plasma
membrane, for exposure to these secreted serpin-type serine protease
inhibitors.
Mammary epithelial cells produce most milk proteins, and, since milk-
derived, immortal mammary epithelial cells express both matriptase and
HAI-1, the milk-derived matriptase-HAI-1 complexes are very likely
produced by mammary epithelial cells (17). Robust zymogen activation of
matriptase apparently takes places in these mammary epithelial cells during
lactation since a large amount of matriptase-HAI-1 complexes are present in
milk (Fig. 8). Since the activated matriptase produced by mammary
epithelial cells is sequestered in HAI-1 complexes and in light of the
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stability of HAI-1/matriptase complexes, it seems very unlikely that the
activated matriptase in serpin complexes is derived from matriptase
liberated from HAI-1 complexes, being inhibited by and forming complexes
with these three serpins. This possibility is made more unlikely by the facts
that 1) the pH of milk does not favor the dissociation of matriptase-HAI-1
complexes, 2) no free HAI-1 was detected in milk as would be expected if
the serpin-bound matriptase was derived from HAI-1 complexes (Figs. 1
and 8), and 3) free α2AP was undetectable in milk and is however found in
complexes with matriptase (Fig. 5). Furthermore, there is probably much
more free α1AT than free ATIII in human milk (20), yet the levels of
matriptase-ATIII complexes are apparently higher than those of α1AT
complexes in human milk. Had matriptase been dissociated from HAI-1
complexes in milk, one would expect α1AT to have a quantitative advantage
in forming complexes with matriptase compared with ATIII due to the large
amount of free α1AT. These observations suggest that there are complicated
biological processes behind the formation of these matriptase-serpin
complexes regarding the cell types that express matriptase and where the
active matriptase encounters these serpins.
The activated matriptase found in these serpin-complexes could be produced
by cell types other than mammary epithelial cells. There are multiple cell
types other than epithelial cells present in the stroma of a lactating
mammary tissues, including fibroblasts, adipocytes, endothelial cells in the
blood vessels, and migrating leukocytes, such as macrophages, plasma cells,
and eosinophils to name a few. Among all these cell types, migrating
leukocytes are a potential source of free active matriptase for what could
subsequently be inhibited by ATIII and α1AT. Peritoneal macrophages have
been reported to express matriptase but not HAI-1 (4). THP-1 human
monocytic cells express matriptase and very low levels of HAI-1 (Fig. 6). In
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the absence of HAI-1, migrating macrophages may secret free active
matriptase. ATIII and α1AT are produced by the liver, are found at high
levels in the blood, and may be transported and deposited in the interstitial
spaces of the lactating mammary tissues, thus finding their way into milk,
with their free forms detected in milk. ATIII has been detected in the
basement membrane bound to heparin sulfate proteosaminoglycan
underneath endothelial cells in blood vessels from a variety of tissues (33).
The mRNA of α1AT has also been detected in the lactating mammary
tissues, suggesting that local expression of the serpin may also contribute to
its presence in milk (6). Therefore, an appealing hypothesis for the presence
of both free and matriptase-complexed ATIII and α1AT in human milk is
that matriptase is activated in migrating leukocytes and/or plasma cells
when these cells are extravasating and migrating through the basement
membrane of capillaries in the lactating mammary gland, where both
serpins are deposited.
The biology of the inhibition of matriptase by α2AP may be different from
the other two secreted serpins since free α2AP was not detected in human
milk by immunoblot analysis (Fig. 8). Transcytosis of α2AP into milk
apparently does not occur to any significant extent compared with the levels
of ATIII and α1AT (Fig. 5). The presence of matriptase-α2AP complexes in
the absence of free α2AP in human milk suggests that α2AP may be
expressed by the same cells that are expressing and activating matriptase,
resulting in the formation of α2AP complexes before shedding into the
extracellular milieu, in a fashion similar to HAI-1. In contrast to ATIII for
which expression is restricted to hepatocytes, α2AP has been detected in
several other tissues, including kidney, intestine, striated muscle, testis,
hippocampus, and placenta (22). It is of interest to determine whether and
what cell types might produce α2AP in mammary tissues in future studies.
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Unlike Kunitz-type protease inhibitors, such as HAI-1, which inhibit
proteases by forming very tight but reversible complexes, the mode of
protease inhibition by serpin-type serine protease inhibitors has been
considered to be a “suicide” or “single-use” approach due to its distinctive
conformational alteration for inhibiting serine proteases. Serpin-type serine
protease inhibitors inactivate their target proteases by binding to them
covalently in a 1:1 stoichiometry. Protease inactivation by serpin inhibitors
involves the attack of the target protease on the P1-P1′ bond in the reactive
center loop of the serpins that results in the trapping of the protease in
complexes with serpin inhibitors and deforms the protease catalytic triad (9,
34). In the case of the 110-kDa matriptase-serpin complexes, the covalent
linkage between the reactive centers of the serpins and active site triad
serine of matriptase held both proteins together under boiled and
nonreduced conditions (Fig. 2). The binding, inhibition, and trapping of
serine proteases by serpins likely significantly disrupts the active site triad
and substrate binding pocket of proteases since the activation-associated
epitope recognized by the mAb M69 is no longer present on the 110-kDa
complexes (Figs. 2 and 5).
In summary, in this study, we have purified three novel matriptase
complexes containing secreted serpins. These secreted serpins may provide
the long-sought answer for the question as to how the proteolytic activity of
matriptase is controlled in those cells that express no or very low levels of
HAI-1. In addition, the presence of free, active matriptase in the
extracellular milieu and the formation of matriptase-serpin complexes
suggest that these serpins could be useful tools to detect active matriptase in
those cells that express very low levels of or no HAI-1. Despite their
common ability to inhibit matriptase, secreted serpins, at least for ATIII and
α1AT, are likely to be responsible to the control of active matriptase
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possibly produced by migrating leukocytes in contrast to HAI-1, which
regulates matriptase in mammary epithelial cells. Therefore, in the lactating
mammary tissues, there appears to be two sources of matriptases: epithelial
matriptase and stromal matriptase. The major difference between these two
matriptase forms is their inhibitions by different inhibitor systems.
GRANTS
This study was supported by NIH R01CA096851 and R01CA104944 (to Lin,
C.-Y.) and by the Maryland Cigarette Restitution Fund Program.
View larger version
Fig. 1. Matriptase complexes in human milk. Human milk was
fractionated by CM ionic exchange chromatography. The column
fractions (8-26) were subjected to immunoblot analysis using
matriptase monoclonal antibody (mAb) M32 (A) and hepatocyte
growth factor activator inhibitor-1 (HAI-1) mAb M19 (B). Two distinct matriptase-
containing complexes were detected by matriptase mAb M32, as indicated. The
majority of matriptase was detected at 95 kDa in the column fractions 10-21. A small
portion of matriptase was detected at 110 kDa in column fractions 18-24. HAI-1 mAb
M19 detected only the 95-kDa but not the 110-kDa form.
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Fig. 2. Immunological characterization and purification of 110-kDa
matriptase complexes. A: immunological comparison of the 2 milk-
derived matriptase complexes. The pooled 110-kDa complex-enriched CM column
fractions (19-25), which contained similar levels of both 110- and 95-kDa matriptase
complexes (lane 1, L), were subjected to immunoprecipitation (IP) with immobilized
matriptase mAb 21-9, activated matriptase mAb M69, and HAI-1 mAb M19,
respectively, as indicated (21-9 IP, M69 IP, and M19 IP). The unbound (UB) fractions
were collected (lanes 2, 5, and 8). After being washed, the proteins, captured by
immobilized mAbs beads, were eluted by glycine buffer, pH 2.4, and immediately
neutralized. Two sequential elutions were performed (lanes 3, 6, and 9 for elution 1,
E1; lanes 4, 7, and 10 for elution 2, E2). All these samples were analyzed by
immunoblot with matriptase mAb M32. The 95-kDa matriptase-HAI-1 complexes were
immunodepleted by these 3 immobilized mAbs and disappeared from the unbound
fractions (lanes 2, 5, and 8). The 95-kDa matriptase-HAI-1 complexes were eluted as
95-kDa complexes and dissociated 70-kDa form (lanes 3, 4, 6, 7, 9, and 10). The
110-kDa matriptase-containing complexes were immunodepleted only by mAb M32-
Sepharose beads (lane 2) but not by mAb M69-Sepharose beads (lane 5) and M19-
Sepharose beads (lane 8). A matriptase species with a size of 90 kDa was seen in
the unbound fractions after removal of 95-kDa matriptase-HAI-1 complexes by anti-
HAI-1 mAb M19 (lane 8). The 90-kDa matriptase complexes turned out also to be
matriptase-HAI-1 complexes, which contained a degraded HAI-1 fragment that lost the
epitope recognized by M19 mAb (data not shown). B and C: immunoaffinity
purification of 110-kDa matriptase-containing complexes. The 110-kDa matriptase
complex-enriched CM fractions (from Fig. 1) were passed through HAI-1 mAb M19-
Sepharose column to remove the 95-kDa matriptase-HAI-1 complexes. The 110-kDa
complexes were then purified by immunoaffinity chromatography with matriptase mAb
21-9. The eluted proteins were mixed with SDS sample buffer containing no reducing
agents and incubated at room temperature (lanes 1) or 95°C (lanes 2) for 5 min
before SDS-PAGE. The eluted proteins in SDS gel were either stained with
Coomassie blue (B) or analyzed by immunoblot using matriptase mAb M32 (C). MW,
molecular weight markers. The 110-kDa matriptase complexes were eluted as major
proteins from immunoaffinity column and were stable in boiling SDS sample buffer
(lanes 2). Several minor proteins were also seen in eluted fractions, including the
dissociated, active matriptase species (70 kDa), 90-kDa matriptase-HAI-1
complexes (also seen in A, lane 8), and polymeric immunoglobulin receptor. The 90-
kDa complexes contain matriptase and a shorter HAI-1 fragment in which the epitope
recognized by M19 mAb was lost (data not shown). The 90-kDa matriptase-HAI-1
complexes were completely dissociated after boiling and detected as 70-kDa bands
by matriptase mAb M32 mAb (C, lane 2).
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Fig. 3. Analysis and identification of the milk-derived 110-kDa
complexes. Left: analysis of 110-kDa matriptase complexes by
diagonal gel electrophoresis. Immunoaffinity-purified 110-kDa
matriptase complexes (see Fig. 2) were mixed with SDS sample buffer containing no
reducing agents, incubated at 95°C for 5 min, and then resolved by SDS-PAGE (1st D
Boiled). A gel strip was then sliced out, boiled in 1× SDS sample buffer in the
presence of reducing agents, and electrophoresed on a second SDS gel (2nd D
Reduced). The gels were stained with Coomassie blue. After this procedure, the 110-
kDa matriptase complexes were converted to 80-kDa and 45-kDa protein spots, as
indicated in the dashed rectangle. Right: proteomic protein identification of the
subunits of the 110-kDa matriptase-containing complexes. Both 80-kDa and 45-kDa
protein spots derived from 110-kDa matriptase complexes were excised, trypsinized,
and then subjected to liquid chromatography-tandem mass spectrometry analysis (LC-
MS/MS) for protein identification. Database search revealed that there were 11 tryptic
fragments derived from the 45-kDa protein spots matched to 6 stretches of amino
acid sequences at the noncatalytic domain of matriptase. These 6 stretches of amino
acid sequences are double-underlined. The 80-kDa spots yielded many tryptic
fragments, which matched to at least 4 different proteins. Among these tryptic
fragments, 5 fragments matched to 4 stretches of amino acid sequences of the serine
protease domain of matriptase; 30 fragments matched to 8 stretches of amino acid
sequences of antithrombin III (ATIII); 3 fragments matched to 2 stretches of amino acid
sequences of α1-antitrypsin (α1AT); 2 fragments matched to 2 stretches of amino acid
sequences of α2 antiplasmin (α2AP). These stretches of amino acid sequences
matched to the 80-kDa protein spots are underlined. The deduced amino acid
sequences were obtained from GenBank, and the Accession Numbers are
AAD42765 for matriptase, AAB40025 for ATIII, AAB59371 for α1AT, and CAA85350
for α2AP.
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Fig. 4. The milk-derived 110-kDa species are matriptase-serpin
complexes (A–D). Immunological confirmation of 110-kDa matriptase complexes
containing the secreted serpins, ATIII, α1AT, and α2AP. To confirm that the 110-kDa
matriptase complexes contain secreted serpins, purified 110-kDa matriptase
complexes (lanes 1), blood-derived ATIII preparation (lanes 2), α1AT preparation
(lanes 3), and α2AP preparation (lanes 4) were examined by immunoblot analyses
with matriptase mAb M32 (A, matriptase), antithrombin antibody (B, ATIII), α1AT
antibody (C), and α2AP antibody (D). Roughly, 2 ng of 110-kDa complexes were used
for A, B, and C, 100 ng for D. E: schematic representation of 110-kDa matriptase-
serpin complexes and their dissociation by reducing agents. Milk-derived 110-kDa
matriptase complexes contain secreted serpins covalently linked with activated
matriptase in which the noncatalytic domain (NCD: 45 kDa) is linked with serine
protease domain (SPD: 25 kDa) by a disulfide bond (S-S). Reducing agents, such as
DTT, break the disulfide linkage but not the covalent bond linking the matriptase serine
protease domain with the serpin inhibitors and convert the 110-kDa complexes into
the NCD of matriptase with a size of 45-kDa and 80-kDa protein fragments, which
contain the SPD of matriptase covalently linked to the secreted serpins.
View larger version
Fig. 5. Expression analysis of matriptase and its endogenous
inhibitors, HAI-1, ATIII, α1AT, and α2AP. Defatted human milk was
subjected to Western blot analyses using matriptase mAb M32
(MTP), activated matriptase mAb M69 (MTP*), HAI-1 mAb M19 (HAI-1), ATIII antibody,
α1AT antibody, and α2AP.
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Fig. 6. Expression of matriptase and HAI-1 protein in human
leukemia cell lines. Twenty-five micrograms of whole cell lysates from
a variety of human cell lines, as indicated, were resolved by SDS-PAGE and probed
with matriptase mAb M32 or with HAI-1 MAb M19. Origin of human cell lines: T47D,
human breast cancer (positive control); U937, myelogenous leukemia; THP-1,
myelogenous leukemia; K562, myelogenous leukemia; Jurkat, T-cell leukemia; HuT78,
T-cell leukemia; CCRF-HSB-2, T-cell leukemia; CCRF-SB, B-cell leukemia; RS4; 4,
B-cell leukemia; Daudi, B-cell lymphoma (Burkitt's); ST486, B-cell lymphoma
(Burkitt's).
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Fig. 1.
Matriptase complexes in human milk. Human milk was fractionated by CM ionic
exchange chromatography. The column fractions (8-26) were subjected to
immunoblot analysis using matriptase monoclonal antibody (mAb) M32 (A) and
hepatocyte growth factor activator inhibitor-1 (HAI-1) mAb M19 (B). Two distinct
matriptase-containing complexes were detected by matriptase mAb M32, as
indicated. The majority of matriptase was detected at 95 kDa in the column fractions
10-21. A small portion of matriptase was detected at 110 kDa in column fractions
18-24. HAI-1 mAb M19 detected only the 95-kDa but not the 110-kDa form.
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Fig. 2.
Immunological characterization and purification of 110-kDa matriptase complexes.
A: immunological comparison of the 2 milk-derived matriptase complexes. The
pooled 110-kDa complex-enriched CM column fractions (19-25), which contained
similar levels of both 110- and 95-kDa matriptase complexes (lane 1, L), were
subjected to immunoprecipitation (IP) with immobilized matriptase mAb 21-9,
activated matriptase mAb M69, and HAI-1 mAb M19, respectively, as indicated (21-
9 IP, M69 IP, and M19 IP). The unbound (UB) fractions were collected (lanes 2, 5,
and 8). After being washed, the proteins, captured by immobilized mAbs beads,
were eluted by glycine buffer, pH 2.4, and immediately neutralized. Two sequential
elutions were performed (lanes 3, 6, and 9 for elution 1, E1; lanes 4, 7, and 10 for
elution 2, E2). All these samples were analyzed by immunoblot with matriptase mAb
M32. The 95-kDa matriptase-HAI-1 complexes were immunodepleted by these 3
immobilized mAbs and disappeared from the unbound fractions (lanes 2, 5, and 8).
The 95-kDa matriptase-HAI-1 complexes were eluted as 95-kDa complexes and
dissociated 70-kDa form (lanes 3, 4, 6, 7, 9, and 10). The 110-kDa matriptase-
containing complexes were immunodepleted only by mAb M32-Sepharose beads
(lane 2) but not by mAb M69-Sepharose beads (lane 5) and M19-Sepharose beads
(lane 8). A matriptase species with a size of 90 kDa was seen in the unbound
fractions after removal of 95-kDa matriptase-HAI-1 complexes by anti-HAI-1 mAb
M19 (lane 8). The 90-kDa matriptase complexes turned out also to be matriptase-
HAI-1 complexes, which contained a degraded HAI-1 fragment that lost the epitope
recognized by M19 mAb (data not shown). B and C: immunoaffinity purification of
110-kDa matriptase-containing complexes. The 110-kDa matriptase complex-
enriched CM fractions (from Fig. 1) were passed through HAI-1 mAb M19-
Sepharose column to remove the 95-kDa matriptase-HAI-1 complexes. The 110-
kDa complexes were then purified by immunoaffinity chromatography with
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matriptase mAb 21-9. The eluted proteins were mixed with SDS sample buffer
containing no reducing agents and incubated at room temperature (lanes 1) or 95°C
(lanes 2) for 5 min before SDS-PAGE. The eluted proteins in SDS gel were either
stained with Coomassie blue (B) or analyzed by immunoblot using matriptase mAb
M32 (C). MW, molecular weight markers. The 110-kDa matriptase complexes were
eluted as major proteins from immunoaffinity column and were stable in boiling SDS
sample buffer (lanes 2). Several minor proteins were also seen in eluted fractions,
including the dissociated, active matriptase species (70 kDa), 90-kDa matriptase-
HAI-1 complexes (also seen in A, lane 8), and polymeric immunoglobulin receptor.
The 90-kDa complexes contain matriptase and a shorter HAI-1 fragment in which the
epitope recognized by M19 mAb was lost (data not shown). The 90-kDa matriptase-
HAI-1 complexes were completely dissociated after boiling and detected as 70-kDa
bands by matriptase mAb M32 mAb (C, lane 2).
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Fig. 3.
Analysis and identification of the milk-derived 110-kDa complexes. Left: analysis of
110-kDa matriptase complexes by diagonal gel electrophoresis. Immunoaffinity-
purified 110-kDa matriptase complexes (see Fig. 2) were mixed with SDS sample
buffer containing no reducing agents, incubated at 95°C for 5 min, and then resolved
by SDS-PAGE (1st D Boiled). A gel strip was then sliced out, boiled in 1× SDS
sample buffer in the presence of reducing agents, and electrophoresed on a second
SDS gel (2nd D Reduced). The gels were stained with Coomassie blue. After this
procedure, the 110-kDa matriptase complexes were converted to 80-kDa and 45-
kDa protein spots, as indicated in the dashed rectangle. Right: proteomic protein
identification of the subunits of the 110-kDa matriptase-containing complexes. Both
80-kDa and 45-kDa protein spots derived from 110-kDa matriptase complexes were
excised, trypsinized, and then subjected to liquid chromatography-tandem mass
spectrometry analysis (LC-MS/MS) for protein identification. Database search
revealed that there were 11 tryptic fragments derived from the 45-kDa protein spots
matched to 6 stretches of amino acid sequences at the noncatalytic domain of
matriptase. These 6 stretches of amino acid sequences are double-underlined. The
80-kDa spots yielded many tryptic fragments, which matched to at least 4 different
proteins. Among these tryptic fragments, 5 fragments matched to 4 stretches of
amino acid sequences of the serine protease domain of matriptase; 30 fragments
matched to 8 stretches of amino acid sequences of antithrombin III (ATIII); 3
fragments matched to 2 stretches of amino acid sequences of α1-antitrypsin (α1AT);
2 fragments matched to 2 stretches of amino acid sequences of α2 antiplasmin
(α2AP). These stretches of amino acid sequences matched to the 80-kDa protein
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spots are underlined. The deduced amino acid sequences were obtained from
GenBank, and the Accession Numbers are AAD42765 for matriptase, AAB40025
for ATIII, AAB59371 for α1AT, and CAA85350 for α2AP.
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Fig. 4.
The milk-derived 110-kDa species are matriptase-serpin complexes (A–D).
Immunological confirmation of 110-kDa matriptase complexes containing the
secreted serpins, ATIII, α1AT, and α2AP. To confirm that the 110-kDa matriptase
complexes contain secreted serpins, purified 110-kDa matriptase complexes (lanes
1), blood-derived ATIII preparation (lanes 2), α1AT preparation (lanes 3), and α2AP
preparation (lanes 4) were examined by immunoblot analyses with matriptase mAb
M32 (A, matriptase), antithrombin antibody (B, ATIII), α1AT antibody (C), and α2AP
antibody (D). Roughly, 2 ng of 110-kDa complexes were used for A, B, and C, 100
ng for D. E: schematic representation of 110-kDa matriptase-serpin complexes and
their dissociation by reducing agents. Milk-derived 110-kDa matriptase complexes
contain secreted serpins covalently linked with activated matriptase in which the
noncatalytic domain (NCD: 45 kDa) is linked with serine protease domain (SPD: 25
kDa) by a disulfide bond (S-S). Reducing agents, such as DTT, break the disulfide
linkage but not the covalent bond linking the matriptase serine protease domain with
the serpin inhibitors and convert the 110-kDa complexes into the NCD of matriptase
with a size of 45-kDa and 80-kDa protein fragments, which contain the SPD of
matriptase covalently linked to the secreted serpins.
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Fig. 5.
Expression analysis of matriptase and its endogenous inhibitors, HAI-1, ATIII, α1AT,
and α2AP. Defatted human milk was subjected to Western blot analyses using
matriptase mAb M32 (MTP), activated matriptase mAb M69 (MTP*), HAI-1 mAb
M19 (HAI-1), ATIII antibody, α1AT antibody, and α2AP.
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Fig. 6.
Expression of matriptase and HAI-1 protein in human leukemia cell lines. Twenty-five
micrograms of whole cell lysates from a variety of human cell lines, as indicated,
were resolved by SDS-PAGE and probed with matriptase mAb M32 or with HAI-1
MAb M19. Origin of human cell lines: T47D, human breast cancer (positive control);
U937, myelogenous leukemia; THP-1, myelogenous leukemia; K562, myelogenous
leukemia; Jurkat, T-cell leukemia; HuT78, T-cell leukemia; CCRF-HSB-2, T-cell
leukemia; CCRF-SB, B-cell leukemia; RS4; 4, B-cell leukemia; Daudi, B-cell
lymphoma (Burkitt's); ST486, B-cell lymphoma (Burkitt's).
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